An Indian court has allowed Dr Reddy’s Laboratories Ltd to manufacture and export generic versions of Novo Nordisk A/S’s obesity and diabetes drugs, ahead of global patent expiries in 2026.

Novo Nordisk’s petition to block production of semaglutide was rejected by the Delhi High Court in its December 2 interim order. The court allowed Dr Reddy’s to export to markets without patent protection, while accepting the Indian company’s commitment that it will not sell the products in the local market until Novo’s patent lapses.

Semaglutide is the main ingredient in Novo’s diabetes medicine Ozempic and its weight-loss drug Wegovy.

Dr Reddy’s, one of India’s largest drugmakers, plans to supply non-branded semaglutide to over 80 countries, joining a growing race among generics from India and Chin

See Full Page